1. A class action lawsuit has been filed against LifeMD, Inc. (LFMD). 2. LifeMD is accused of issuing misleading statements about financial outlook. 3. The company allegedly overstated its market position and earnings guidance. 4. LifeMD shares dropped 44% after true facts were revealed. 5. Investors have until October 27, 2025, to join the lawsuit.
Lawsuits often negatively affect stock prices; 44% drop indicates severe loss of investor confidence.
The lawsuit highlights serious allegations that can greatly undermine LifeMD's credibility.
Immediate impact expected due to ongoing legal proceedings, affecting investor sentiment quickly.
PHILADELPHIA, Sept. 4, 2025 /PRNewswire/ -- Berger Montague PC, national plaintiffs' law firm, announces a class action lawsuit against LifeMD, Inc. (NASDAQ:LFMD) ("LifeMD" or the "Company") on behalf of investors who purchased or acquired shares during the period from May 7, 2025 through August 5, 2025 (the "Class Period").
Investor Deadline: Investors who purchased or acquired LifeMD securities during the Class Period may, no later than October 27, 2025, seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE.
LifeMD, headquartered in New York, New York, is a telehealth provider offering direct-to-patient virtual care and pharmacy services.
According to the suit, LifeMD issued materially false and/or misleading statements regarding its business and financial outlook. Specifically, the Company is accused of overstating its competitive position and raising its 2025 guidance without adequately accounting for escalating customer acquisition costs—particularly within its RexMD segment and for obesity-related drugs like Wegovy and Zepbound.
When the true facts were revealed, LifeMD shares fell 44%, or $5.31 per share, in a single trading session.
If you are a LifeMD investor and would like to learn more about this action, CLICK HERE or please contact Berger Montague: Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015, or Caitlin Adorni at cadorni@bergermontague.com or (267)764-4865.
About Berger Montague
Berger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco, Chicago, Malvern, PA, and Toronto has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.
For more information or to discuss your rights, please contact:
Andrew Abramowitz
Senior Counsel
Berger Montague
(215) 875-3015
aabramowitz@bergermontague.com
Caitlin Adorni
Director of Portfolio and Institutional Client Monitoring Services
Berger Montague
(267) 764-4865
cadorni@bergermontague.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/berger-montague-pc-investigates-securities-claims-against-lifemd-inc-nasdaq-lfmd-302546707.html
SOURCE Berger Montague